Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.

Winters AC, Bernt KM.

Front Pediatr. 2017 Feb 9;5:4. doi: 10.3389/fped.2017.00004. Review.

2.

Therapy-related myeloid neoplasms in children and adolescents.

Cho HW, Choi YB, Yi ES, Lee JW, Sung KW, Koo HH, Yoo KH.

Blood Res. 2016 Dec;51(4):242-248. doi: 10.5045/br.2016.51.4.242.

3.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z.

4.

Therapy-related myeloid neoplasms - what have we learned so far?

Zahid MF, Parnes A, Savani BN, Litzow MR, Hashmi SK.

World J Stem Cells. 2016 Aug 26;8(8):231-42. doi: 10.4252/wjsc.v8.i8.231. Review.

5.

Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.

Jabbour EJ, Garcia-Manero G, Strati P, Mishra A, Al Ali NH, Padron E, Lancet J, Kadia T, Daver N, O'Brien S, Steensma DP, Sekeres MA, Gore SD, Dezern A, Roboz GJ, List AF, Kantarjian HM, Komrokji RS.

Cancer. 2015 Mar 15;121(6):876-82. doi: 10.1002/cncr.29145.

6.

Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.

Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2014 Dec;20(12):1975-81. doi: 10.1016/j.bbmt.2014.08.013.

7.

Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation.

Kim SY, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M, Deeg HJ.

Haematologica. 2014 Dec;99(12):1868-75. doi: 10.3324/haematol.2014.108977.

8.

Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome.

Shimura Y, Kuroda J, Sasaki N, Uchiyama H, Ohshiro M, Matsumura Y, Nagoshi H, Mizutani S, Kobayashi T, Matsumoto Y, Horiike S, Taniwaki M.

Case Rep Oncol. 2014 Mar 13;7(1):188-94. doi: 10.1159/000360905.

9.

The evolving challenge of therapy-related myeloid neoplasms.

Churpek JE, Larson RA.

Best Pract Res Clin Haematol. 2013 Dec;26(4):309-17. doi: 10.1016/j.beha.2013.09.001. Review.

10.

Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.

Jabbour E, Ghanem H, Huang X, Ravandi F, Garcia-Manero G, O'Brien S, Faderl S, Pierce S, Choi S, Verstovsek S, Brandt M, Cortes J, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):93-7. doi: 10.1016/j.clml.2013.10.013.

11.

Therapy-related myelodysplasia and acute myeloid leukemia.

Bhatia S.

Semin Oncol. 2013 Dec;40(6):666-75. doi: 10.1053/j.seminoncol.2013.09.013.

12.

Transplantation for myelodysplastic syndromes 2013.

Vaughn JE, Scott BL, Deeg HJ.

Curr Opin Hematol. 2013 Nov;20(6):494-500. doi: 10.1097/MOH.0b013e328364f547. Review.

13.

Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.

Akhtari M, Bhatt VR, Tandra PK, Krishnamurthy J, Horstman H, Dreessen A, Chen PX, Armitage JO.

Cancer Biol Ther. 2013 Dec;14(12):1077-88. doi: 10.4161/cbt.26342. Review.

14.

Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study.

Jabbour E, Mathisen MS, Garcia-Manero G, Champlin R, Popat U, Khouri I, Giralt S, Kadia T, Chen J, Pierce S, Koca E, Daver N, Tanaka M, Rondon G, Oran B, Parmar S, Kantarjian H, de Lima M.

Am J Hematol. 2013 Mar;88(3):198-200. doi: 10.1002/ajh.23371.

15.

Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?

Gyurkocza B, Deeg HJ.

Blood Rev. 2012 Nov;26(6):247-54. doi: 10.1016/j.blre.2012.08.002. Review.

16.

Guidelines on haemovigilance of post-transfusional iron overload.

Remacha A, Sanz C, Contreras E, De Heredia CD, Grifols JR, Lozano M, Nuñez GM, Salinas R, Corral M, Villegas A; Spanish Society of Blood Transfusion.; Spanish Society of Haematology and Haemotherapy..

Blood Transfus. 2013 Jan;11(1):128-39. doi: 10.2450/2012.0114-11. Review. No abstract available.

17.

Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.

Deeg HJ, Scott BL, Fang M, Shulman HM, Gyurkocza B, Myerson D, Pagel JM, Platzbecker U, Ramakrishnan A, Radich JP, Sandmaier BM, Sorror M, Stirewalt DL, Wilson WA, Storb R, Appelbaum FR, Gooley T.

Blood. 2012 Aug 16;120(7):1398-408. doi: 10.1182/blood-2012-04-423046.

18.

Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

Al-Kadhimi Z, Gul Z, Rodriguez R, Chen W, Smith D, Mitchell A, Abidi M, Ayash L, Deol A, Lum L, Forman S, Ratanatharathorn V, Uberti J.

Biol Blood Marrow Transplant. 2012 Nov;18(11):1734-44. doi: 10.1016/j.bbmt.2012.06.004.

19.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.

Karoopongse E, Deeg HJ.

Expert Rev Clin Immunol. 2012 May;8(4):373-81. doi: 10.1586/eci.12.18. Review.

20.

Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.

Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC, Garcia-Manero G, Wang SA, Hasserjian RP.

J Clin Oncol. 2012 Jul 1;30(19):2340-7. doi: 10.1200/JCO.2011.38.7340.

Supplemental Content

Support Center